New Investigational Drug’s Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects

Abstract

Currently, cervical cancer (CC) is the fourth recorded widespread cancer among women globally. There are still many cases of metastatic or recurring disease discovered, despite the incidence and fatality rates declining due to screening identification and innovative treatment approaches. Palliative chemotherapy continues to be the standard of care for patients who are not contenders for curative therapies like surgery and radiotherapy. This article seeks to provide a thorough and current summary of therapies that have been looked into for the management of CC. The authors emphasize the ongoing trials while reviewing the findings of clinical research. Agents that use biological mechanisms to target different molecular pathways such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribosepolymerase (PARP), and epigenetic biological mechanisms epitomize and offer intriguing research prospects.

Keywords:

• Cervical cancer
• malignant
• clinical trials
• targeted therapy
• therapeutic option

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Additional information

Funding

The One of authors, Ekta Shirbhate is thankful to Department of Science and Technology (DST), New Delhi for providing research fellowship under DST-Inspire Fellowship Prorgramme (Fellowship No: IF210097). Harish Rajak, the corresponding author, thanks the ICMR, New Delhi for assisting his work financially through an extra-mural research project (Grant number: 58/33/2020/PHA/BMS).